Interplay Between Natriuretic Peptides and Left Atrial Mechanics and the Relation to Recurrence of Atrial Fibrillation Following Catheter Ablation

Overview

Journal Int J Cardiovasc Imaging

Publisher Springer

Specialty Radiology

Date 2023 Jul 10

PMID 37428246

Authors

Flemming Javier Olsen

Stine Darkner

Jens Peter Goetze

Xu Chen

Kristoffer Henningsen

Steen Pehrson

Jesper Hastrup Svendsen

Tor Biering-Sorensen

Affiliations

Soon will be listed here.

Abstract

The relationship between natriuretic peptides and atrial distension is not fully understood. We sought to examine their interrelationship and how they relate to atrial fibrillation (AF) recurrence following catheter ablation. We analyzed patients enrolled in the AMIO-CAT trial (amiodarone vs. placebo for reducing AF recurrence). Echocardiography and natriuretic peptides were assessed at baseline. Natriuretic peptides included mid-regional proANP (MR-proANP) and N-terminal proBNP (NT-proBNP). Atrial distension was assessed by left atrial strain measured by echocardiography. The endpoint was AF recurrence within 6 months after a 3-month blanking period. Logistic regression was used to assess the association between log-transformed natriuretic peptides and AF. Multivariable adjustments were made for age, gender, randomization, and left ventricular ejection fraction. Of 99 patients, 44 developed AF recurrence. No differences in natriuretic peptides nor echocardiography were observed between the outcome groups. In unadjusted analyses, neither MR-proANP nor NT-proBNP were significantly associated with AF recurrence [MR-proANP: OR = 1.06 (0.99-1.14), per 10% increase; NT-proBNP: OR = 1.01 (0.98-1.05), per 10% increase]. These findings were consistent after multivariable adjustments. However, atrial strain significantly modified the association between MR-proANP and AF (p for interaction = 0.009) such that MR-proANP was associated with AF in patients with high atrial strain [OR = 1.24 (1.06-1.46), p = 0.008, per 10% increase] but not in patients with low atrial strain. In patients with high atrial strain, an MR-proANP > 116 pmol/L posed a fivefold higher risk of AF recurrence [HR = 5.38 (2.19-13.22)]. Atrial natriuretic peptide predicts AF recurrence in patients with preserved atrial distension. Assessing atrial strain may assist the interpretation of natriuretic peptides.

References

Darkner S, Chen X, Hansen J, Pehrson S, Johannessen A, Nielsen J . Recurrence of arrhythmia following short-term oral AMIOdarone after CATheter ablation for atrial fibrillation: a double-blind, randomized, placebo-controlled study (AMIO-CAT trial). Eur Heart J. 2014; 35(47):3356-64. DOI: 10.1093/eurheartj/ehu354. View

Hoit B . Left atrial size and function: role in prognosis. J Am Coll Cardiol. 2013; 63(6):493-505. DOI: 10.1016/j.jacc.2013.10.055. View

Jiang H, Wang W, Wang C, Xie X, Hou Y . Association of pre-ablation level of potential blood markers with atrial fibrillation recurrence after catheter ablation: a meta-analysis. Europace. 2016; 19(3):392-400. DOI: 10.1093/europace/euw088. View

Yoshihara F, Nishikimi T, Sasako Y, Hino J, Kobayashi J, Minatoya K . Plasma atrial natriuretic peptide concentration inversely correlates with left atrial collagen volume fraction in patients with atrial fibrillation: plasma ANP as a possible biochemical marker to predict the outcome of the maze procedure. J Am Coll Cardiol. 2002; 39(2):288-94. DOI: 10.1016/s0735-1097(01)01719-3. View

Ganesan A, Shipp N, Brooks A, Kuklik P, Lau D, Lim H . Long-term outcomes of catheter ablation of atrial fibrillation: a systematic review and meta-analysis. J Am Heart Assoc. 2013; 2(2):e004549. PMC: 3647286. DOI: 10.1161/JAHA.112.004549. View

Daniels L, Lee N, Hsu J . Natriuretic Peptides for Predicting Left Atrial Reverse Remodeling After Atrial Fibrillation Ablation: Too Much of a Stretch?. JACC Clin Electrophysiol. 2018; 2(2):159-161. DOI: 10.1016/j.jacep.2016.02.005. View

Olsen F, Darkner S, Chen X, Pehrson S, Johannessen A, Hansen J . Left atrial structure and function among different subtypes of atrial fibrillation: an echocardiographic substudy of the AMIO-CAT trial. Eur Heart J Cardiovasc Imaging. 2020; 21(12):1386-1394. DOI: 10.1093/ehjci/jeaa222. View

Dietz J . Mechanisms of atrial natriuretic peptide secretion from the atrium. Cardiovasc Res. 2005; 68(1):8-17. DOI: 10.1016/j.cardiores.2005.06.008. View

Kirchhof P, Benussi S, Kotecha D, Ahlsson A, Atar D, Casadei B . 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J. 2016; 37(38):2893-2962. DOI: 10.1093/eurheartj/ehw210. View

10.

den Uijl D, Delgado V, Tops L, Ng A, Boersma E, Trines S . Natriuretic peptide levels predict recurrence of atrial fibrillation after radiofrequency catheter ablation. Am Heart J. 2010; 161(1):197-203. DOI: 10.1016/j.ahj.2010.09.031. View

11.

Wakula P, Neumann B, Kienemund J, Thon-Gutschi E, Stojakovic T, Manninger M . CHA2DS2-VASc score and blood biomarkers to identify patients with atrial high-rate episodes and paroxysmal atrial fibrillation. Europace. 2017; 19(4):544-551. DOI: 10.1093/europace/euw101. View

12.

Virani S, Alonso A, Benjamin E, Bittencourt M, Callaway C, Carson A . Heart Disease and Stroke Statistics-2020 Update: A Report From the American Heart Association. Circulation. 2020; 141(9):e139-e596. DOI: 10.1161/CIR.0000000000000757. View

13.

Goetze J, Friis-Hansen L, Rehfeld J, Nilsson B, Svendsen J . Atrial secretion of B-type natriuretic peptide. Eur Heart J. 2006; 27(14):1648-50. DOI: 10.1093/eurheartj/ehl109. View

14.

Nakanishi K, Fukuda S, Yamashita H, Kosaka M, Shirai N, Tanaka A . Pre-Procedural Serum Atrial Natriuretic Peptide Levels Predict Left Atrial Reverse Remodeling After Catheter Ablation in Patients With Atrial Fibrillation. JACC Clin Electrophysiol. 2018; 2(2):151-158. DOI: 10.1016/j.jacep.2015.12.010. View

15.

Darkner S, Goetze J, Chen X, Henningsen K, Pehrson S, Svendsen J . Natriuretic Propeptides as Markers of Atrial Fibrillation Burden and Recurrence (from the AMIO-CAT Trial). Am J Cardiol. 2017; 120(8):1309-1315. DOI: 10.1016/j.amjcard.2017.07.018. View

16.

Mujovic N, Marinkovic M, Lenarczyk R, Tilz R, Potpara T . Catheter Ablation of Atrial Fibrillation: An Overview for Clinicians. Adv Ther. 2017; 34(8):1897-1917. PMC: 5565661. DOI: 10.1007/s12325-017-0590-z. View

17.

Cameli M, Lisi M, Righini F, Massoni A, Natali B, Focardi M . Usefulness of atrial deformation analysis to predict left atrial fibrosis and endocardial thickness in patients undergoing mitral valve operations for severe mitral regurgitation secondary to mitral valve prolapse. Am J Cardiol. 2012; 111(4):595-601. DOI: 10.1016/j.amjcard.2012.10.049. View

18.

van den Berg M, Crijns H, van Veldhuisen D, van Gelder I, de Kam P, Lie K . Atrial natriuretic peptide in patients with heart failure and chronic atrial fibrillation: role of duration of atrial fibrillation. Am Heart J. 1998; 135(2 Pt 1):242-4. DOI: 10.1016/s0002-8703(98)70088-2. View

19.

Liang J, Dixit S . Early Recurrences During the Blanking Period after Atrial Fibrillation Ablation. J Atr Fibrillation. 2018; 10(5):1726. PMC: 6006974. DOI: 10.4022/jafib.1726. View

20.

Mabuchi N, Tsutamoto T, Maeda K, Kinoshita M . Plasma cardiac natriuretic peptides as biochemical markers of recurrence of atrial fibrillation in patients with mild congestive heart failure. Jpn Circ J. 2000; 64(10):765-71. DOI: 10.1253/jcj.64.765. View